Jan 23 (Reuters) - BIOFRONTERA AG:
* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES 12-MONTH FOLLOW-UP RESULTS OF THE PHASE III TRIAL FOR DAYLIGHT PDT
* OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS A CLEAR TREND TOWARDS IMPROVED EFFICACY
* OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS LOWER RECURRENCE RATES FOR AMELUZ Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 